Sundberg AL - Search Results

1

Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro.

Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von Mehren M, Shchaveleva I, Simmons HH, Marks JD, Adams GP. Robinson MK, et al. Among authors: sundberg al. Br J Cancer. 2008 Nov 4;99(9):1415-25. doi: 10.1038/sj.bjc.6604700. Epub 2008 Oct 7. Br J Cancer. 2008. PMID: 18841159 Free PMC article.

2

Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression.

Carlsson J, Ren ZP, Wester K, Sundberg AL, Heldin NE, Hesselager G, Persson M, Gedda L, Tolmachev V, Lundqvist H, Blomquist E, Nistér M. Carlsson J, et al. Among authors: sundberg al. J Neurooncol. 2006 Mar;77(1):33-45. doi: 10.1007/s11060-005-7410-z. J Neurooncol. 2006. PMID: 16200342 Review.

3

Treatment of cultured glioma cells with the EGFR-TKI gefitinib ("Iressa", ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibition.

Sundberg AL, Almqvist Y, Tolmachev V, Carlsson J. Sundberg AL, et al. Eur J Nucl Med Mol Imaging. 2003 May;30(5):727-9. doi: 10.1007/s00259-003-1129-x. Epub 2003 Mar 7. Eur J Nucl Med Mol Imaging. 2003. PMID: 12740721

4

Cellular uptake of radioiodine delivered by trastuzumab can be modified by the addition of epidermal growth factor.

Nordberg E, Steffen AC, Persson M, Sundberg AL, Carlsson J, Glimelius B. Nordberg E, et al. Among authors: sundberg al. Eur J Nucl Med Mol Imaging. 2005 Jul;32(7):771-7. doi: 10.1007/s00259-005-1761-8. Epub 2005 Mar 12. Eur J Nucl Med Mol Imaging. 2005. PMID: 15765233

5

Cellular retention of radioactivity and increased radiation dose. Model experiments with EGF-dextran.

Sundberg AL, Blomquist E, Carlsson J, Steffen AC, Gedda L. Sundberg AL, et al. Nucl Med Biol. 2003 Apr;30(3):303-15. doi: 10.1016/s0969-8051(02)00421-3. Nucl Med Biol. 2003. PMID: 12745022

6

Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF.

Sundberg AL, Almqvist Y, Orlova A, Blomquist E, Jensen HJ, Gedda L, Tolmachev V, Carlsson J. Sundberg AL, et al. Eur J Nucl Med Mol Imaging. 2003 Oct;30(10):1348-56. doi: 10.1007/s00259-003-1308-9. Epub 2003 Aug 21. Eur J Nucl Med Mol Imaging. 2003. PMID: 12937952

7

[(111)In]Bz-DTPA-hEGF: Preparation and in vitro characterization of a potential anti-glioblastoma targeting agent.

Sundberg AL, Orlova A, Bruskin A, Gedda L, Carlsson J, Blomquist E, Lundqvist H, Tolmachev V. Sundberg AL, et al. Cancer Biother Radiopharm. 2003 Aug;18(4):643-54. doi: 10.1089/108497803322287736. Cancer Biother Radiopharm. 2003. PMID: 14503960

8

[177Lu]Bz-DTPA-EGF: Preclinical characterization of a potential radionuclide targeting agent against glioma.

Sundberg AL, Gedda L, Orlova A, Bruskin A, Blomquist E, Carlsson J, Tolmachev V. Sundberg AL, et al. Cancer Biother Radiopharm. 2004 Apr;19(2):195-204. doi: 10.1089/108497804323071977. Cancer Biother Radiopharm. 2004. PMID: 15186600

9

Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors.

Velikyan I, Sundberg AL, Lindhe O, Höglund AU, Eriksson O, Werner E, Carlsson J, Bergström M, Långström B, Tolmachev V. Velikyan I, et al. Among authors: sundberg al. J Nucl Med. 2005 Nov;46(11):1881-8. J Nucl Med. 2005. PMID: 16269603 Free article.

10

Enhancing the effect of radionuclide tumor targeting, using lysosomotropic weak bases.

Sundberg AL, Steffen AC. Sundberg AL, et al. Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):279-87. doi: 10.1016/j.ijrobp.2006.07.1369. Int J Radiat Oncol Biol Phys. 2007. PMID: 17189076

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11 results

Search Page

Filters